In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters.
Jacek Piatek, Hanna Krauss, Arleta Ciechelska-Rybarczyk...
https://pubmed.ncbi.nlm.nih.gov/32403297/Actively Recruiting
Led by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz · Updated on 2025-12-15
200
Participants Needed
3
Research Sites
52 weeks
Total Duration
Researchers are investigating the effects of a nine-strain synbiotic called Vivatlac Synbiotikum in adults diagnosed with moderate to severe Irritable Bowel Syndrome IBS. This multi-center, randomized, double-blind, placebo-controlled clinical trial uses the World Gastroenterology Organisations IBS questionnaire for diagnosis and the IBS Severity of Symptoms Scale IBS-SSS to assess symptom severity, including a four-week screening phase to evaluate symptoms and stool characteristics. Participants will take one capsule daily before bedtime for 36 weeks, receiving either the Vivatlac Synbiotic or an identical placebo capsule. Each synbiotic capsule contains a blend of nine probiotic bacteria strains totaling 4.5 billion colony forming units and 63 mg of fructooligosaccharides as a prebiotic. The study compares treatment effects against placebo over the treatment period. During the trial, participants will be assessed at multiple time points using several measures IBS severity IBS-SSS, global improvement IBS-GIS, adequate symptom relief IBS-AR, stool form Bristol Stool Form Scale, quality of life IBS-QoL, and emotional suppression Courtauld Emotional Control Scale. These evaluations occur before treatment and at intervals up to 36 weeks. The trial includes safety monitoring and lasts for the full 36-week treatment duration.
CONDITIONS
Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
J
Jacek Piatek, Prof. Dr.
H
Henning Sommermeyer, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 4 weeks
Participants are screened for eligibility to participate in the trial.
Participants complete a patient diary to evaluate IBS symptoms and stool characteristics during this time.
Duration - 36 weeks
Participants take one capsule of either Vivatlac Synbiotic or placebo daily before bedtime for 36 weeks.
Visits occur at the start of treatment and after 4, 8, 12, 24, and 36 weeks for assessments.
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jacek Piatek, Hanna Krauss, Arleta Ciechelska-Rybarczyk...
https://pubmed.ncbi.nlm.nih.gov/32403297/Henning Sommermeyer, Krzysztof Chmielowiec, Malgorzata Bernatek...
https://pubmed.ncbi.nlm.nih.gov/38794741/Henning Sommermeyer, Jacek Piątek
https://pubmed.ncbi.nlm.nih.gov/39065261/Henning Sommermeyer, Hanna M Pituch, Dorota Wultanska...
https://pubmed.ncbi.nlm.nih.gov/34070727/J Piatek, H Sommermeyer, M Bernatek...
https://pubmed.ncbi.nlm.nih.gov/30574800/Henning Sommermeyer, Krzysztof Chmielowiec, Malgorzata Bernatek...
https://pubmed.ncbi.nlm.nih.gov/39599697/The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Lead Sponsor